目的 探讨丹鹿通督片联合柳氮磺吡啶治疗强直性脊柱炎的临床疗效。方法 选取2015年7月-2016年9在河南省直第三人民医院接受治疗的强直性脊柱炎患者90例，随机分为对照组（45例）和治疗组（45例）。对照组患者口服柳氮磺吡啶肠溶片，第1周2片/次，第2周3片/次，第3周及以后4片/次，均为2次/d。治疗组在对照组的基础上口服丹鹿通督片，4片/次，3次/d。两组患者均连续治疗2个月。评价两组患者临床疗效，同时比较两组患者治疗前后BASDAI、BASFI和临床症状评分以及血清C反应蛋白（CRP）、白介素-1β（IL-1β）、IL-4、IL-10和IL-17等血清学指标变化。结果 治疗后，对照组和治疗组总有效率分别为77.78%、95.56%，两组总有效率比较差异有统计学意义（P<0.05）。治疗后，两组BASDAI、BASFI评分均明显下降（P<0.05）；且治疗组这些指标降低水平优于对照组（P<0.05）。治疗后，两组下腰背疼痛、外周关节疼痛、外周关节肿胀等症状评分均显著降低（P<0.05）；且治疗组上述临床症状评分降低更显著（P<0.05）。治疗后，两组CRP、IL-1β、IL-17均显著降低，而IL-4、IL-10均显著升高，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组上述血清学指标改善程度优于对照组，两组比较差异具有统计学意义（P<0.05）。结论 丹鹿通督片联合柳氮磺吡啶治疗强直性脊柱炎的临床效果显著，有利于临床症状的改善及降低机体炎症反应，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Danlu Tongdu Tablets combined with sulfasalazine in treatment of ankylosing spondylitis. Methods Patients (90 cases) with ankylosing spondylitis in Third Provincial Hospital of Henan Province from July 2015 to September 2016 were randomly divided into control (45 cases) and treatment (45 cases) groups. Patients in the control group were po administered with Sulfasalazine Enteric-coated Tablets, 2 tablets/time for the first week, 3 tablets/time for the second week, and 4 tablets/time for the third and beyond weeks, twice daily. Patients in the treatment group were po administered with Danlu Tongdu Tablets on the basis of the control group, 4 tablets/time, three times daily. Patients in two groups were treated for 2 months. After treatment, the clinical efficacy was evaluated, and BASDAI, BASFI, and clinical symptom scores, the serological index changes of CRP, IL-1β, IL-4, IL-10, and IL-17 in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 77.78% and 95.56%, respectively, and there was difference between two groups (P<0.05). After treatment, BASDAI and BASFI scores in two groups were significantly decreased (P<0.05). And these indicators levels in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the scores of low lumbar back pain, peripheral joint pain, and swelling in two groups were significantly decreased (P<0.05). The decrease degree of clinical symptom score in the treatment group was more significantly than that in the control group (P<0.05). After treatment, CRP, IL-1β, and IL-17 in two groups were significantly decreased, while IL-4 and IL-10 were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the improvement degree of serological indexes in the treatment group was better than that in the control group, with significant difference between two groups (P<0.05). Conclusion Danlu Tongdu Tablets combined with sulfasalazine has significant clinical effect in treatment of ankylosing spondylitis, which is conducive to the improvement of clinical symptoms and reduce the inflammatory reaction, and has a certain clinical application value.